Icon (ICLR) Releases FY18 Earnings Guidance

Icon (NASDAQ:ICLR) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $5.89-6.09 for the period, compared to the Thomson Reuters consensus estimate of $6.02. The company issued revenue guidance of $2.52-2.64 billion (taking into account ASC 606), compared to the consensus revenue estimate of $1.90 billion.

Several brokerages have recently commented on ICLR. Credit Suisse Group raised shares of Icon to a buy rating and set a $131.00 target price on the stock in a report on Friday. Mizuho reaffirmed a neutral rating and set a $114.00 target price (up from $109.00) on shares of Icon in a report on Thursday. ValuEngine raised shares of Icon from a hold rating to a buy rating in a research note on Tuesday. BidaskClub raised shares of Icon from a strong sell rating to a sell rating in a research note on Friday, February 9th. Finally, SunTrust Banks reissued a buy rating and issued a $133.00 price objective on shares of Icon in a research note on Monday, January 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Icon presently has a consensus rating of Buy and an average price target of $126.00.

Shares of Icon (NASDAQ ICLR) traded up $3.67 during trading hours on Friday, reaching $113.86. 478,700 shares of the company were exchanged, compared to its average volume of 343,806. The company has a market capitalization of $5,967.01, a PE ratio of 21.15, a price-to-earnings-growth ratio of 1.55 and a beta of 0.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.48.

Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, February 15th. The medical research company reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. The firm had revenue of $455.10 million for the quarter, compared to analysts’ expectations of $455.66 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.33 earnings per share. sell-side analysts predict that Icon will post 5.37 EPS for the current fiscal year.

An institutional investor recently raised its position in Icon stock. Vanguard Group Inc. grew its stake in shares of Icon Plc (NASDAQ:ICLR) by 19.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,545 shares of the medical research company’s stock after buying an additional 2,400 shares during the quarter. Vanguard Group Inc.’s holdings in Icon were worth $1,422,000 as of its most recent SEC filing. Institutional investors own 89.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Icon (ICLR) Releases FY18 Earnings Guidance” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/16/icon-iclr-releases-fy18-earnings-guidance.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply